Share Your Testimonial
On October 8, 2024, Soleno Therapeutics provided a regulatory update on DCCR (Diazoxide Choline Controlled-Release) tablets, which are currently undergoing priority review by the FDA as a potential treatment for hyperphagia in individuals with Prader-Willi syndrome (PWS). Although the FDA has moved forward with priority review, it has chosen not to hold an advisory committee meeting at this time.
We have worked diligently over the past several years to ensure that the patient voice is actively heard by FDA. Through initiatives like our patient listening session, the Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting, multiple engagements with the FDA, robust congressional support, and a community petition representing nearly 15,000 individuals, we continually strive to amplify the voices of those affected by PWS and advocate for access to effective treatments.
While it appears there may not be another formal opportunity for our community to share their support for DCCR prior to the Prescription Drug User Fee Act (PDUFA) date of December 27th, we encourage you and/or your loved ones affected by PWS to contribute a written testimonial. PWSA | USA will gather and securely hold these testimonials, ensuring we are prepared should the FDA request additional community input. Testimonial submission is entirely optional, but we want to offer our community members another outlet to be heard in case additional input is needed.
If you or someone you love living with PWS would like to submit additional testimony, please fill out the form below to share your story. We respectfully request that all submissions be received by November 3, 2024. Thank you for your ongoing support and advocacy. Together, we can continue to make a difference in bringing effective treatments to those living with PWS.